Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg
Provided By GlobeNewswire
Last update: Mar 20, 2025
LONDON and GAITHERSBURG, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Hikma Pharmaceuticals PLC (Hikma, Group), the multinational generic pharmaceutical company, announces the approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg, by Health Canada for the treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult patients.
Read more at globenewswire.com4.54
-0.08 (-1.73%)
Find more stocks in the Stock Screener
EBS Latest News and Analysis
7 days ago - ChartmillTuesday's after hours session: top gainers and losersAs the regular session of the US market concludes on Tuesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
